Top

Published in:

01-10-2014 | Original Article

Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis

Authors: Azadeh Ahmadian, MD, Ashley Brogan, MD, Jeffrey Berman, MD, Aaron L. Sverdlov, MD, PhD, Gustavo Mercier, MD, PhD, Michael Mazzini, MD, Praveen Govender, MD, Frederick L. Ruberg, MD, Edward J. Miller, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 5/2014

Abstract

Background

FDG PET/CT with myocardial perfusion imaging is a useful method for evaluating cardiac sarcoidosis (CS), but interpretation is not standardized. We developed a method for quantification of cardiac FDG PET/CT and evaluated its relationship to conventional interpretation, perfusion defects, clinical events, and immunosuppressive treatment.

Methods and Results

FDG PET/CT with MPI studies performed for CS (n = 38) were retrospectively compared to negative control studies acquired for oncologic indications (n = 10). Quantitative measures of FDG volume-intensity (Cardiac Metabolic Activity, CMA) was performed using standardized uptake values (SUVs). CMA (477.7 ± 909 vs 0.55 ± 2.1 vs 0.3 ± 0.3 g glucose, P = .02) was significantly greater in visually FDG-positive studies compared to visually negative and oncologic negative studies. Among patients with CS, CMA was greater in studies with an EF < 50% (760.3 ± 1,148 vs 87.4 ± 161 g glucose, P = .03) and preceding an adverse clinical event (1,095 ± 1,253 vs 73 ± 144 g glucose, P = .006). CMA was the only independent predictor of events by multivariate analysis. In patients with repeat examinations (n = 7), CMA decreased with prednisone treatment in 5 of 6 patients.

Conclusions

Quantification of FDG uptake in CS correlates with lower EFs, clinical events, and immunosuppression treatment.

Available only for authorised users

Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91. doi:10.1016/j.hrthm.2012.02.010.PubMedCrossRef

Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.PubMedCrossRef

Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.PubMed

Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28. doi:10.1016/j.jcmg.2010.09.015.PubMedCrossRef

Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10. doi:10.1007/s12350-009-9110-0.PubMedCrossRef

Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc Imaging 2013;6:617-26. doi:10.1161/CIRCIMAGING.112.000289.PubMedCrossRef

Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2013. doi:10.1007/s12350-013-9828-6.

Shah B, Srivastava N, Hirsch AE, Mercier G, Subramaniam RM. Intra-reader reliability of FDG PET volumetric tumor parameters: Effects of primary tumor size and segmentation methods. Ann Nucl Med 2012;26:707-14. doi:10.1007/s12149-012-0630-3.PubMedCrossRef

Tilkemeier PL, Cooke CD, Grossman GB, McCallister BD, Ward RP. Standardized reporting of radionuclide myocardial perfusion and function. J Nucl Cardiol 2009;16:650. doi:10.1007/s12350-009-9095-8.CrossRef

10.

Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5.PubMedCrossRef

11.

Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11. doi:10.1016/j.jcmg.2012.10.021.PubMedCrossRef

12.

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36. doi:10.1016/j.jacc.2013.09.022.PubMedCrossRef

13.

Isiguzo MM, Brunken RR, Tchou PP, Xu M, Culver DA. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:50-5.PubMed

Title: Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
Authors: Azadeh Ahmadian, MD
Ashley Brogan, MD
Jeffrey Berman, MD
Aaron L. Sverdlov, MD, PhD
Gustavo Mercier, MD, PhD
Michael Mazzini, MD
Praveen Govender, MD
Frederick L. Ruberg, MD
Edward J. Miller, MD, PhD
Publication date: 01-10-2014
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 5/2014
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-014-9901-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis

Abstract

Background

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Is TOMPOOL (gated blood-pool SPECT processing software) accurate to diagnose right and left ventricular dysfunction in a clinical setting?

I-123 mIBG and Tc-99m myocardial SPECT imaging to predict inducibility of ventricular arrhythmia on electrophysiology testing: A retrospective analysis

Why Quality Counts

A selection of recent, original research papers

Quantification of I-123-meta-iodobenzylguanidine Heart-to-Mediastinum Ratios: Not So Simple After All

F-18 FDG PET/CT in the evaluation of Takayasu arteritis: An experience from the tropics